Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study (Q29775)

From lgbtDB
Jump to navigation Jump to search
No description defined
  • Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study.
  • Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors
Language Label Description Also known as
English
Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study
No description defined
  • Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study.
  • Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors

Statements

Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study. (English)
1 reference
The risk of venous thromboembolism (VTE) with gender-affirming hormone therapy (GAHT) in transgender and gender non-binary (TNB) youth is unclear. (English)
1 reference
To identify the rate of VTE in a cohort of TNB youth followed in the transgender health clinic at Boston Children's Hospital, and to investigate the impact of congenital thrombophilia diagnosis on the use of GAHT. (English)
1 reference
ICD-9 and ICD-10 codes were used to identify eligible individuals, defined as (i) having a diagnosis of gender dysphoria and (ii) venous thromboembolism (VTE). (English)
1 reference
Data were abstracted from a review of medical records. (English)
1 reference
A second data query assessed TNB individuals who had an associated thrombophilia diagnosis. (English)
1 reference
The primary analysis included 1860 individuals. (English)
1 reference
Total 942 individuals (50.6%) had started GAHT at the time of data analysis. (English)
1 reference
Mean age (±SD) at GAHT initiation was 16.8 (±1.9) years. (English)
1 reference
Five thrombotic events were identified in three (0.13%) individuals, all in the setting of additional VTE risk factors. (English)
1 reference
Only two of five thrombotic events occurred while receiving GAHT. (English)
1 reference
The rate of VTE in the GAHT cohort did not statistically differ from the rate of VTE in the non-GAHT cohort (0.1% vs. 0.2%, p = .62). (English)
1 reference
Of the 10 individuals diagnosed with a congenital thrombophilia, two transmasculine individuals received prophylactic anticoagulation prior to GAHT. (English)
1 reference
No VTE has been reported to date in this cohort. (English)
1 reference
In our cohort, VTE was rare in the TNB youth and was not associated with GAHT use. (English)
1 reference
TNB youth with congenital thrombophilia have not developed VTE in the setting of GAHT use to date. (English)
1 reference
November 2024
1 reference
November 2024
1 reference
71
1 reference
11
1 reference
e31284
1 reference
e31284
1 reference